As the second major signalling cascade involved in cancer pathogenesis and one of the most frequently mutated pathways in all human cancers, the BRAF/MEK/ERK pathway has been a major target for clinical therapeutic development, especially in cancers where BRAF mutations are common, such as in melanoma and thyroid cancer. This evidence concerns the gene BRAF and thyroid gland carcinoma.